HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1266806VANI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $8.9M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

VANI Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Vivani Medical, Inc. (VANI), a Healthcare sector company. VANI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $8.9m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Vivani Medical, Inc. reports net income of $-6.4M, free cash flow of $-6.1M. Top institutional holders of VANI by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Tanager Wealth Management LLP, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. VANI trades on the Nasdaq exchange and files with the SEC under CIK 1266806. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VANI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vivani Medical, Inc. directly from SEC EDGAR.

Net Income

Q2 2026

$-6.4M

Free Cash Flow

Q2 2026

$-6.1M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$0.00FY 2025
FY22 FY23 FY24 $0.00FY25 $0.00

Net Income

-13.3% YoY
$-26.6MFY 2025
FY22 $-13.9MFY23 $-25.7MFY24 $-23.5MFY25 $-26.6M

Operating Income

-11.7% YoY
$-27.6MFY 2025
FY22 $-21.2MFY23 $-27.0MFY24 $-24.7MFY25 $-27.6M

EPS (Diluted)

+0.0% YoY
$-0.43FY 2025
FY22 FY23 $-0.50FY24 $-0.43FY25 $-0.43

Total Assets

-5.2% YoY
$39.4MFY 2025
FY22 $51.1MFY23 $45.8MFY24 $41.6MFY25 $39.4M

Total Debt

FY 2025
FY22 FY23 FY24 FY25

Op. Cash Flow

-17.0% YoY
$-24.3MFY 2025
FY22 $-18.8MFY23 $-23.7MFY24 $-20.8MFY25 $-24.3M

Free Cash Flow

-19.4% YoY
$-25.5MFY 2025
FY22 $-19.1MFY23 $-24.6MFY24 $-21.3MFY25 $-25.5M

Get alerted when VANI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vivani Medical, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of VANI

Put VANI on your watchlist

Track score changes the day Vivani Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is VANI a good stock to buy?

13F Pro's AI-powered analysis of Vivani Medical, Inc. (VANI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VANI are available on the VANI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VANI is classified as a small company.

Which hedge funds own VANI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VANI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vivani Medical, Inc.'s investment landscape.